Testing ABOD2011 for advanced solid tumors after standard treatment
Part of Cancer clinical trials.
This Phase 1 trial tests a new medicine (ABOD2011) in people with advanced solid tumors that have come back or spread after standard treatment. It may help by shrinking tumors and allows researchers to study the tumor by giving medicine directly into it and taking a biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed solid tumor that has returned or spread, and standard treatment didn’t work or wasn’t tolerated
- Your scans show at least one measurable tumor spot, and you have a tumor that can be treated directly (injected) and biopsied
- You must be well enough to do daily activities (ECOG score 0 or 1), weigh over 30 kg, and expected survival is more than 12 weeks
- Your blood/organ tests are sufficient, and if you can become pregnant, you must have a negative pregnancy test
- You must not have had certain treatments recently (anti-cancer therapy in the past 28 days, or radiation in the past 14 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This early Phase 1 study tests OT-A201 (a first-time-in-humans drug) in people with certain relapsed or advanced cancers. It helps doctors learn the safest dose and how the treatment may work for cancers that have already been treated.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.